Smiggles - Your antepenultimate statement doesn't seem to match most of the other points in your post. Margins are absolutely critical to our success so anything that threatens this area is a concern to me. The biggest disappointment for me in 2013 was the end of talk from UNS about device-drug patent extensions. The UNS story remains good but device-drug patent extension would have packed a powerful revenue punch. It also would have been a robust catalyst for moving many approved drugs online VERY quickly. Fortunately, we still have a good business case in numerous areas.
- Forums
- ASX - By Stock
- UNS
- unilife - still bullish after q2 2014 earnings
unilife - still bullish after q2 2014 earnings, page-29
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)